Features of myelodysplasia and/or leukemia
Case no. . | Patient age, y . | Latent period, mo . | Protocol arm . | Type of MDS . | Cytogenetics . | Metaphases abnormal/diploid . | Therapy for MDS/AML . | Survival after MDS, mo . |
|---|---|---|---|---|---|---|---|---|
| 1 | 58 | 15 | FND→R | RARS | 42-46, X, del (X) (q22), del (1) (p34), −3, del (3) (p21), add (5) (q35), +6, der (7) t(7;8) (q36;q11), −8, −10, −11, del (11) (p11.2), del (12) (p11.2), der (15) t(5;15) (q11;p13), add (17) (p11), + 1-7 mar [cp20] | 20/0 | CSFs | 8 |
| 2 | 49 | 34 | R-FND | RAEB | 45, XX, t(3;21) (q26;q22), −7 [10] | 10/10 | 3 | |
| 3 | 42 | 54 | R-FND | RARS | 46, XY, −7, del (12) (p11p12), +mar [19] | 19/1 | CSFs | 11 |
| 4 | 71 | 28 | R-FND | MDS | 46, XX, del (13) (q12q14) [5] | 11/9 | CSFs | 17 |
| 46, XX, −7, +mar [4] | ||||||||
| 46, XX, del (7) (q22), −21, +mar [2] | ||||||||
| 5 | 68 | 57 | R-FND* | AMMoL | 46, XY, del (5) (q31q35), del (7) (q22q34), del (12) (p11p12) [20] | 20/0 | Chemo | 4 |
| 6 | 45 | 31 | ATT† | RAEB | 48, XX, +8, t(16;21) (q24;q21), + 18[18] | 18/2 | Chemo; BMT | 11+ |
| 7 | 56 | 59 | ATT | RAEB | 46, XY, −2, dup (2) (q21q31), −5, add (17) (p13), +2mar [3] | 12/8 | Chemo;BMT | 10 |
| 43-47, XY, −2, dup (2) (q21q31), −5, −7, add (7) (p12), +9, der (16) t(1;16) (q25;p13), add (17) (p13), −19, +1-3mar [9] | ||||||||
| 8 | 75 | 16 | R-FND‡ | AML | 67, XX, −X, +1, +2, −3, +4, −5, +6, −7, +8, −10, −10, −11, −12, −14, −15, −17, +18, −19, +20, +21, −22, −22, −22, +5mar [3] | 10/10 | Declined | 2 |
| 60-67, XX, −X, +1, +2, −3, +4, −5, +6, −7, +8, −10, −10, −11, −12, +13, −14, −15, −17, +18, −19, +20, +21, −22, −22, −22, +4-6mar [cp6] | ||||||||
| 56, XX, +1, +1, +2, −3, −4, +6, +6, +8, −9, −10, −12, −13, +14, −15, +18, +19, +20, +21, +21, −22, −22, +6mar[1] |
Case no. . | Patient age, y . | Latent period, mo . | Protocol arm . | Type of MDS . | Cytogenetics . | Metaphases abnormal/diploid . | Therapy for MDS/AML . | Survival after MDS, mo . |
|---|---|---|---|---|---|---|---|---|
| 1 | 58 | 15 | FND→R | RARS | 42-46, X, del (X) (q22), del (1) (p34), −3, del (3) (p21), add (5) (q35), +6, der (7) t(7;8) (q36;q11), −8, −10, −11, del (11) (p11.2), del (12) (p11.2), der (15) t(5;15) (q11;p13), add (17) (p11), + 1-7 mar [cp20] | 20/0 | CSFs | 8 |
| 2 | 49 | 34 | R-FND | RAEB | 45, XX, t(3;21) (q26;q22), −7 [10] | 10/10 | 3 | |
| 3 | 42 | 54 | R-FND | RARS | 46, XY, −7, del (12) (p11p12), +mar [19] | 19/1 | CSFs | 11 |
| 4 | 71 | 28 | R-FND | MDS | 46, XX, del (13) (q12q14) [5] | 11/9 | CSFs | 17 |
| 46, XX, −7, +mar [4] | ||||||||
| 46, XX, del (7) (q22), −21, +mar [2] | ||||||||
| 5 | 68 | 57 | R-FND* | AMMoL | 46, XY, del (5) (q31q35), del (7) (q22q34), del (12) (p11p12) [20] | 20/0 | Chemo | 4 |
| 6 | 45 | 31 | ATT† | RAEB | 48, XX, +8, t(16;21) (q24;q21), + 18[18] | 18/2 | Chemo; BMT | 11+ |
| 7 | 56 | 59 | ATT | RAEB | 46, XY, −2, dup (2) (q21q31), −5, add (17) (p13), +2mar [3] | 12/8 | Chemo;BMT | 10 |
| 43-47, XY, −2, dup (2) (q21q31), −5, −7, add (7) (p12), +9, der (16) t(1;16) (q25;p13), add (17) (p13), −19, +1-3mar [9] | ||||||||
| 8 | 75 | 16 | R-FND‡ | AML | 67, XX, −X, +1, +2, −3, +4, −5, +6, −7, +8, −10, −10, −11, −12, −14, −15, −17, +18, −19, +20, +21, −22, −22, −22, +5mar [3] | 10/10 | Declined | 2 |
| 60-67, XX, −X, +1, +2, −3, +4, −5, +6, −7, +8, −10, −10, −11, −12, +13, −14, −15, −17, +18, −19, +20, +21, −22, −22, −22, +4-6mar [cp6] | ||||||||
| 56, XX, +1, +1, +2, −3, −4, +6, +6, +8, −9, −10, −12, −13, +14, −15, +18, +19, +20, +21, +21, −22, −22, +6mar[1] |
FND→R indicates fludarabine, mitoxantrone, dexamethasone (FND) followed by rituximab (and interferon) maintenance; RARS, refractory anemia with ringed sideroblasts; CSFs, colony-stimulating factors (including erythropoietin); R-FND, concurrent rituximab and FND; RAEB, refractory anemia with excess blasts; MDS, myelodysplasia that was not precisely categorized morphologically; AMMoL, acute myelomonocytic leukemia; chemo, chemotherapy; ATT, alternating triple therapy (see “Patients and methods”); and BMT, allogeneic marrow/stem cell transplantation.
Additional interventions before AMMoL included splenectomy and R-CHOP.
One course of R-FND before change to ATT.
Therapy also included one course of salvage R-CHOP before AML.